Moreover, our data indicate that IFN treatment protects against worsening lung abnormalities in COVID-19 patients and limits the effects of SARS-CoV-2 infection on reducing CD8+ T cells and increasing IL-6 and TNF-α levels. The gene discussed is IL6; the disease is COVID-19.